The clinical trial, which started to enroll patients in January 2011, is being conducted under an FDA-approved special protocol assessment, says Galena President and CEO Mark Ahn.
But unlike Bear Stearns (nyse: BSC - news - people ) at least, Galena had virtually no leverage, so it isn't forced to sell off assets in a fire sale environment.